Mobile Trading

EMCURE PHARMACEUTICALS LTD.

NSE : EMCUREBSE : 544210ISIN CODE : INE168P01015Industry : Pharmaceuticals & DrugsHouse : Private
BSE1463.00-63.6 (-4.17 %)
PREV CLOSE ( ) 1526.60
OPEN PRICE ( ) 1539.35
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 19663
TODAY'S LOW / HIGH ( )1440.30 1539.95
52 WK LOW / HIGH ( )1226.5 1577.5
Select year
ParticularsMar2024Mar2023Mar2022Mar2021Mar2020
Operational & Financial Ratios
   Earnings Per Share (Rs)27.5029.4236.6221.684.62
   CEPS(Rs)46.3745.4552.3941.0223.30
   DPS(Rs)2.002.003.001.002.50
   Book NAV/Share(Rs)162.17137.48109.02125.04104.23
   Tax Rate(%)27.4524.8127.7636.324.49
Margin Ratios
   Core EBITDA Margin(%)18.1219.3722.2419.7113.49
   EBIT Margin(%)14.2115.7619.2113.696.94
   Pre Tax Margin(%)10.7212.2516.2710.522.02
   PAT Margin (%)7.779.2111.756.701.93
   Cash Profit Margin (%)12.3813.4815.8411.878.08
Performance Ratios
   ROA(%)7.398.9711.156.721.79
   ROE(%)19.4525.2133.1920.195.43
   ROCE(%)19.8721.9726.5619.759.00
   Asset Turnover(x)0.950.970.951.000.93
   Sales/Fixed Asset(x)1.531.681.621.671.57
   Working Capital/Sales(x)6.477.4713.0220.21-24.07
Efficiency Ratios
   Fixed Capital/Sales(x)0.650.600.620.600.64
   Receivable days94.3288.4984.9776.5274.07
   Inventory Days78.2184.7790.4678.4780.50
   Payable days193.72194.85188.82132.95137.31
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)0.000.000.000.000.00
   Price/Book(x)0.000.000.000.000.00
   Yield(%)
   EV/Net Sales(x)0.300.320.330.320.43
   EV/Core EBITDA(x)1.571.551.401.552.78
   EV/EBIT(x)2.101.981.692.306.04
   EV/CE(x)0.400.410.480.430.54
   M Cap / Sales0.000.000.000.000.00
Growth Ratio
   Net Sales Growth(%)11.232.23-3.3219.967.02
   Core EBITDA Growth(%)4.86-11.939.9461.19-6.83
   EBIT Growth(%)0.37-16.3434.26136.36-34.58
   PAT Growth(%)-6.10-20.0367.84316.06-51.91
   EPS Growth(%)-6.51-19.6658.20369.04-57.14
Financial Stability Ratios
   Total Debt/Equity(x)0.710.881.051.021.15
   Current Ratio(x)1.331.271.151.090.93
   Quick Ratio(x)0.850.810.670.650.52
   Interest Cover(x)4.074.506.534.321.41
   Total Debt/Mcap(x)

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER
© 2018 Ratnakar Securities Pvt. Ltd. All rights reserved.
Designed, Developed & Content Powered by  Accord Fintech Pvt. Ltd.
CLOSE X

Filing complaints on SCORES Easy & quick

  • > Register on SCORES portal (link:https://scores.gov.in)
  • > Mandatory details for filing complaints on SCORES
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • > Benefits:
    • Effective communication
    • Speedy redressal of the grievances
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.